Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.
Shanghai Clinical Research Center, Chinese Academy of Sciences, Shanghai, China.
Adv Exp Med Biol. 2018;1088:329-346. doi: 10.1007/978-981-13-1435-3_15.
Cancer is a prevalent disease with high mortality and morbidity. Muscle atrophy is a severe and disabling clinical condition that frequently accompanies cancer development such as muscle atrophy in pancreatic cancer, lung cancer, and bladder cancer. The majority of cancer patients are accompanied with cachexia. Cancer-associated cachexia is characterized by weight loss and muscle atrophy. Muscle wasting is a pivotal feature of cancer cachexia. Muscle atrophy refers to the reduction of muscle mass caused by muscle itself or the dysfunction of nervous system. Muscle atrophy causes serious clinical consequences such as physical impairment, poor life quality, reduced tolerance to treatments, and short survival. Although many reports have studied cancer-related muscle atrophy, there is still no clear understanding of it. Here we will describe the prevalence, mechanisms, pathophysiological effects, and current clinical treatments of muscle atrophy in cancer.
癌症是一种常见的疾病，死亡率和发病率都很高。肌肉萎缩是一种严重且致残的临床病症，常伴随着癌症的发展，如胰腺癌、肺癌和膀胱癌中的肌肉萎缩。大多数癌症患者伴有恶病质。癌相关性恶病质的特征是体重减轻和肌肉萎缩。肌肉消耗是癌性恶病质的关键特征。肌肉萎缩是指由于肌肉本身或神经系统功能障碍导致的肌肉质量减少。肌肉萎缩会导致严重的临床后果，如身体功能障碍、生活质量下降、对治疗的耐受性降低和生存时间缩短。尽管有许多报道研究了与癌症相关的肌肉萎缩，但对其仍缺乏清晰的认识。在这里，我们将描述癌症中肌肉萎缩的流行率、机制、病理生理影响以及当前的临床治疗方法。
